INCRHealthcare · Drug Manufacturers - Specialty & GenericINCR Stock Forecast: InterCure Ltd. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 13 of 100 as at 1 Aug 2026 — in the weakest quartile.
INCR stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores InterCure Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (82): The share price has been relatively steady.
Growth (1): Sales and profits are flat, shrinking, or growing more slowly than they were.
The rank is the raw material. Whether the rules would actually own InterCure Ltd. — and when they’d sell — is the membership.
INCR stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on INCR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Of the 11 most recent actions, 5 moved their price target up and 5 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Apr 2023 | TD Cowen | Maintains | Outperform | $10 → $5.00 |
| 11 Dec 2017 | Barclays | Initiates | Equal-Weight | $40 |
| 14 Nov 2017 | Credit Suisse | Maintains | Outperform | $68 → $54 |
| 13 Nov 2017 | Keybanc | Maintains | Overweight | $68 → $46 |
| 10 Nov 2017 | Baird | Maintains | Outperform | $67 → $46 |
| 17 Aug 2016 | Jefferies | Maintains | Buy | $56 → $55 |
| 12 Aug 2016 | Goldman Sachs | Maintains | Buy | $60 → $62 |
| 18 Apr 2016 | Avondale Partners | Maintains | Market Perform | $39 → $47 |
| 1 Sept 2015 | Jefferies | Upgrade | Buy | $50 → $51 |
| 27 May 2015 | Jefferies | Maintains | Hold | $35 → $37 |
| 12 Feb 2015 | Baird | Upgrade | Outperform | $26 → $29 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
INCR analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
InterCure Ltd. (INCR) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 22.2×
- Price / sales
- 0.2×
- Price / book
- 0.1×
- EV / EBITDA
- 9.1×
Cheaper than 36% of US stocks
Cheaper than 92% of US stocks
Cheaper than 90% of US stocks
Cheaper than 42% of US stocks
- Revenue growth (YoY)
- 23.9%
- Earnings growth (YoY)
- 7.5%
- Gross margin
- 31.9%
- Operating margin
- −9.0%
- Net margin
- −13.2%
Higher than 75% of US stocks
Higher than 47% of US stocks
Higher than 39% of US stocks
Higher than 26% of US stocks
Higher than 18% of US stocks
- Return on equity
- −9.3%
- Return on assets
- −5.8%
- Dividend yield
- —
Higher than 36% of US stocks
Higher than 31% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
INCR vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. INCR appears on the weeks it earns a place.
Frequently asked questions about INCR stock
Is INCR stock a buy right now?
Of the 12 analysts covering InterCure Ltd., 8 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks InterCure Ltd. 13 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank INCR?
As at 1 Aug 2026, InterCure Ltd. ranks 13 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (82 of 100).
What is the INCR stock forecast for 2030?
No analyst covering InterCure Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for INCR are extrapolating price history, which says nothing about the business.
How has INCR stock performed over the past year?
InterCure Ltd. returned -33.8% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does InterCure Ltd. do?
Intercure Ltd. is a leading pharmaceutical company focused on the development, production, and distribution of cannabis-based products.
About InterCure Ltd.
Intercure Ltd. is a leading pharmaceutical company focused on the development, production, and distribution of cannabis-based products. It stands at the forefront of the medical cannabis industry, leveraging advanced cultivation techniques and proprietary R&D to provide high-quality treatments for a range of medical conditions. Intercure's extensive portfolio includes both therapeutic and wellness products designed to meet the needs of patients and healthcare providers. The company is engaged in several strategic partnerships and collaborations with global leaders in the pharmaceutical and wellness sectors, enhancing its market reach and innovation capabilities. Intercure's operations and distribution networks span multiple countries, positioning it as a key player in the rapidly evolving cannabis market. Through its commitment to rigorous scientific research and regulatory compliance, Intercure is instrumental in advancing the acceptance and integration of medical cannabis into mainstream healthcare solutions. Its active participation in clinical studies and contribution to cannabinoid pharmacology underscores its significant role in the field, supporting informed decisions and elevating health outcomes.
CEO Mr. Alexander Rabinovich · 285 employees · Israel · https://www.intercure.co